AbCellera Biologics Reports Q2 2025 Financial Results

AbCellera Biologics ( (ABCL) ) has issued an announcement.

AbCellera Biologics reported its financial results for Q2 2025, highlighting a net loss of $34.7 million, which is an improvement from the previous year’s loss. The company also initiated dosing in a Phase 1 clinical trial for ABCL635, a potential treatment for vasomotor symptoms associated with menopause, marking its transition to a clinical-stage company. Additionally, AbCellera received authorization to begin Phase 1 trials for ABCL575 and advanced ABCL688 into IND-enabling studies, demonstrating significant progress in its pipeline. With over $750 million in available liquidity, AbCellera is well-positioned to continue executing its strategic initiatives.

The most recent analyst rating on (ABCL) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on AbCellera Biologics stock, see the ABCL Stock Forecast page.

Spark’s Take on ABCL Stock

According to Spark, TipRanks’ AI Analyst, ABCL is a Neutral.

AbCellera Biologics faces significant financial headwinds with declining revenues and increasing losses, but maintains a strong balance sheet and liquidity position. Recent corporate events and strategic advancements in drug candidates provide potential long-term growth, though immediate financial pressures persist. Technical indicators and corporate developments support a moderately positive outlook.

To see Spark’s full report on ABCL stock, click here.

More about AbCellera Biologics

AbCellera Biologics Inc. is a clinical-stage biotechnology company that focuses on discovering and developing antibody-based medicines in the fields of endocrinology, women’s health, immunology, and oncology.

Average Trading Volume: 6,207,705

Technical Sentiment Signal: Buy

Current Market Cap: $1.3B

For detailed information about ABCL stock, go to TipRanks’ Stock Analysis page.